Why has the prognosis for muscle-invasive bladder cancer not significantly improved after decades of therapeutic advancements?

Why has the prognosis for muscle-invasive bladder cancer not significantly improved after decades of therapeutic advancements? Expert Rev Anticancer Ther. 2020 Mar 24;:1-3 Authors: Goto T, Miyamoto H PMID: 32208041 [PubMed - as supplied by publisher]
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Related Links:

Conclusions: Most cancers may be insensitive to social development. Internal factors, including aging, may be a key factor for the occurrence of cancer. PMID: 32462031 [PubMed - in process]
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
ConclusionsScreening for ADL impairments is needed for older cancer survivors as Katz ADL disability differs by cancer type, stage, and age with greater impairment with advanced age and stage.Implications for cancer survivorsInterventions to address ADL limitations should be considered for older cancer survivors.
Source: Journal of Cancer Survivorship - Category: Cancer & Oncology Source Type: research
In conclusion, FOXM1 and FANCD2 can be used as prognostic factors that are associated with high risk of recurrence and with anticancer drug resistance properties in NMIBC patients.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
rdo Ribeiro Extracellular vesicles (EVs) are small membrane vesicles released by all cells and involved in intercellular communication. Importantly, EVs cargo includes nucleic acids, lipids, and proteins constantly transferred between different cell types, contributing to autocrine and paracrine signaling. In recent years, they have been shown to play vital roles, not only in normal biological functions, but also in pathological conditions, such as cancer. In the multistep process of cancer progression, EVs act at different levels, from stimulation of neoplastic transformation, proliferation, promotion of angiogenesis,...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Bladder cancer diagnosis still relies mainly on morphologic/classical pathology, which gives quickly the most important parameters needed, such as stage, grade and the presence of bad prognosticators (lymphovascular invasion, carcinoma in situ, variant histology). During the last 8 years, much progress has been made from a molecular point of view. Much new evidence has allowed us to gain deeper insight into not only the development of bladder cancer but also its complexity, and is leading us to potential new ways of treatment.
Source: Diagnostic Histopathology - Category: Pathology Authors: Tags: Mini-symposium: Nephrourology Source Type: research
Maintenance immunotherapy after successful chemotherapy for patients with advanced urothelial cancers is a new standard of care, says author.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
ConclusionWe found that 1-in-11 cancer survivors developed a SPC. Given the increasing number of cancer survivors and the importance of SPC as a cause of cancer death, there is a need for increased screening for and prevention of SPC.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
In conclusion, we identified that PTPN6 may be a novel prognostic biomarker in BC based on the TCGA database. Further clinical trials are needed to confirm our observations and mechanisms underlying the prognostic value of PTPN6 in BC also deserve further experimental exploration. PMID: 32454905 [PubMed - in process]
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
An international, much-anticipated phase III clinical trial that could change standard-of-care treatment for patients with malignant pleural mesothelioma will open soon, pending COVID-19 pandemic restrictions. The randomized trial will be studying the effectiveness of the immunotherapy drug durvalumab (Imfinzi) when used in combination with chemotherapy drugs pemetrexed (Alimta) and cisplatin for mesothelioma. Opening dates may vary by center because of the COVID-19 pandemic that has slowed or stalled clinical trials everywhere. Durvalumab produces an antibody that helps a patient’s own immune system kill tumor cell...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Purpose of review To review recent literature related to urologic malignancies in patients with neurogenic lower urinary tract dysfunction (NLUTD). We performed a literature search of electronic databases (PubMed, ScienceDirect, Scopus, and CIANHL), with a focus on articles published between January 2015 and December 2019. Recent findings Recent reports demonstrate a lower incidence of bladder cancer in the NLUTD population than previously found, although still significantly higher than the general population. Bladder cancer in patients with NLUTD is usually diagnosed at a younger age, and is associated with higher ra...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: NEUROUROLOGY AND INCONTINENCE: Edited by John Heesakkers and Frank Martens Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology